Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: Therapeutic effect of intravesical administration of paclitaxel solubilized with poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate) in an orthotopic bladder cancer model

Figure 3

Paclitaxel concentration in bladder tumor after intravesical treatment. After intravesical administration of PTX-30W or PTX-CrEL, the paclitaxel concentration in bladder tumor was analyzed using LC-MS/MS. In the PTX-30W group, the paclitaxel concentration in the bladder tumors was 7719 ± 3274 ng/g, which was significantly higher than that in the PTX-CrEL group (4905 ± 2412 ng/g; p = 0.0147).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us